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The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
treatment algorithm recommends intra-articular (IA) hyaluronic acid (HA) for management of knee
osteoarthritis (OA) as second-line treatment in patients who remain symptomatic despite use of non-
steroidal anti-inﬂammatory drugs (NSAIDs). This recommendation is based upon accumulating
evidence that IA HA provides a signiﬁcant beneﬁt in knee OA. There is good evidence that IA HA
injections reduce pain and increase function in knee OA, and the beneﬁts are long-lasting as compared
with IA corticosteroids. Evidence from real-life studies of repeat courses of IA HA demonstrates an
improvement in pain or function lasting up to 40 months (12 months after the last injection cycle), a
reduction in use of concomitant analgesia by up to 50%, and suggests that there may be a delay in the
need for total knee replacement (TKR) of around 2 years. The clinical beneﬁt of IA HA on knee OA may
be 2-fold: (i) mechanical viscosupplementation of the joint (allowing lubrication and shock absorption)
and (ii) the re-establishment of joint homeostasis through induction of endogenous HA production,
which continues long after the exogenous injection has left the joint. The magnitude of the clinical
effect may be different for different HA products, but this has not been proven so far and requires
further investigation. IA HA injections are generally considered to be safe, although a slightly higher
number of cases of local reactions and post-injection non-septic arthritis has been reported with high
molecular weight cross-linked HAs. The use of IA HA in knee OA patients with mild–moderate disease,
and for more severe patients wishing to delay TKR surgery, is recommended by the ESCEO task force.
Further investigation into the OA patient types most likely to beneﬁt from IA HA is warranted.
Viscosupplementation with IA HA is a safe and effective component of the multi-modal management of
knee OA.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm
recommends intra-articular (IA) hyaluronic acid (HA) for advanced
pharmacological management of knee osteoarthritis (OA) in
patients who remain severely symptomatic despite use of non-
steroidal anti-inﬂammatory drugs (NSAIDs) [1]. While there is
increasing evidence that HA injections provide a signiﬁcant beneﬁt
in knee OA [2–4], the level of recommendation afforded to HA
by international and national societies varies (Table 1) [1,5–7].
The European League Against Rheumatism (EULAR) guidelinesr HS Journals, Inc. This is an openrecommend IA HA based upon level 1B evidence for both pain
reduction and joint functional improvement [5]. Both the Ameri-
can College of Rheumatology (ACR) guidelines and ESCEO algo-
rithm recommend IA HA in patients whose symptoms persist
despite prior treatments [1,6]. The 2014 Osteoarthritis Research
Society International (OARSI) guidelines give an “uncertain” rec-
ommendation to IA HA [7]. This “uncertain” classiﬁcation “is not
intended to be a negative recommendation or preclude use of that
therapy. Rather it indicates a role for physician–patient interaction
in determining whether this treatment may have merit in the
context of its risk: beneﬁt proﬁle and the individual characteristics,
co-morbidities, and preferences of the patient” [7], leading to the
prescription of IA HA for speciﬁc clinical phenotypes and not for all
individuals with knee OA. Besides, surprisingly and against all the
evidence from literature and daily clinical practice, OARSI guide-
lines attributed to IA HA injection a “risk score” superior to theaccess article under the CC BY-NC-ND license
Table 1
Recommendations for the use of intra-articular hyaluronic acid for knee osteoarthritis
Guideline committee Recommendation for IA HA
European Society for Clinical and Economic
Aspects of Osteoporosis and Osteoarthritis
(ESCEO)
Recommended for advanced pharmacological management in persistent symptomatic patients if still
symptomatic after intermittent or longer cycles of oral NSAIDs.
European League Against Rheumatism (EULAR) Evidence to support efﬁcacy. Limitations: logistic and cost issues.
American College of Rheumatology (ACR) No recommendation in the initial management. Conditionally recommended if no satisfactory response to prior
treatments.
Osteoarthritis Research Society International
(OARSI)
Uncertain but possible for knee OA after physician patient interaction. Not appropriate for multi-joint OA.
IA HA, intra-articular hyaluronic acid; OA, osteoarthritis; NSAIDs, non-steroidal anti-inﬂammatory drugs.
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co-morbidities.Review of the evidence base for efﬁcacy of IA HA
Numerous meta-analyses have investigated the evidence for
the efﬁcacy of IA HA in treating the symptoms of knee OA [2–4,8–
11]. Table 2 summarizes the meta-analyses published to date and
their main characteristics [2–4,8–18]. The Cochrane review of
2006 included 76 trials of a number of different HA products
mostly administered at weekly intervals for 3–5 weeks, in
comparison with placebo, IA corticosteroids, NSAIDs, and other
therapies [8]. The analysis found that viscosupplementation is an
effective treatment for OA of the knee. Beneﬁcial effects on pain,
function, and patient global assessment at different post-
injection time periods were noted, but especially at 5–13 weeks
post-injection which showed a percent improvement from base-
line of 28–54% for pain and 9–32% for function [8]. It was noted
that the magnitude of the clinical effect was different for differentTable 2
Characteristics and results of the meta-analyses published on intra-articular hyaluronic
Study/analysis details Number of
articles
analyzed
Main outcome
Lo et al. [12] 22 Pain change at M1
Wang et al. [13] versus placebo 20 Pain change
Arrich et al. [14] versus placebo 22 Pain during move
Modawal et al. [15] versus placebo 11 Pain VAS
Bellamy et al. [8] versus placebo 40 Pain/function (WM
Medina et al. [16] versus placebo Pain
Low MW versus Hylan G-F20
(Reichenbach et al. [17])
13 Pain at endpoint
Therapeutic trajectory versus IA
corticosteroids (Bannuru et al. [11])
7 Pain change from
Therapeutic trajectory (Bannuru et al. [2]) 54 Pain change from
Colen et al. [18] versus placebo/HAs 74 Pain change from
Rutjes et al. [3] versus placebo 71 Pain difference vs.
endpoint
US-approved HAs (n ¼ 6) versus placebo
(Miller and Block [10])
29 Pain/function at en
Bannuru et al. [9] versus NSAIDs 5 Pain at endpoint
Bannuru et al. [4] versus placebo/other
options
52 Pain/function at M
ES, effect size; HA, hyaluronic acid; IA, intra-articular; M, month; MW, molecular weig
weighted mean difference.products, and considerable heterogeneity of outcomes was found
between trials [8].
A recent network meta-analysis was performed on 137 studies
comprising 33,243 participants using a Bayesian random-effects
model to determine the comparative effectiveness of pharmaco-
logical interventions for knee OA [4]. For pain, all interventions
signiﬁcantly outperformed oral placebo, with the exception of
paracetamol; the most efﬁcacious treatment was found to be IA HA
with an effect size (ES) of 0.63 (95% central credible interval [CrI]:
0.39–0.88). The least effective treatment was paracetamol (ES:
0.18, 95% CrI: 0.04–0.33) [4]. For function, all interventions with
the exception of IA corticosteroids and paracetamol were signiﬁ-
cantly superior to oral placebo, and for stiffness most of the
treatments did not differ signiﬁcantly from one another. It was
notable that the use of the IA delivery method itself was found to
have a signiﬁcant effect, with an ES of 0.29 (95% CrI: 0.04–0.54) for
IA placebo compared with oral placebo. Nonetheless, when
compared with IA placebo, a statistically signiﬁcant ES of 0.34
(CrI: 0.26–0.42) was observed for IA HA on pain at 3 months, which
is of the magnitude observed in conventional meta-analyses,acid injections in knee OA
Results/quantiﬁcation of effect (95% CI) Conclusion
–4 ES: 0.32 (0.17–0.47) Intermediate
Pooled change þ Positive
ment VAS Mean change: 7 mm at W22–30 Negative
Between group difference: 18 mm at
W8–12
Positive
moderate
D or SMD) 28% to 54% Reduction in pain at W5–13 Positive
— Positive
ES: on between group difference 0.27 in
favor of Hylan, but more post-injection
ﬂares
Discourage
Hylan use
baseline ES: 0.22 (0.05 to 0.49) at W8 in favor of
IA HA
Positive from
W8
ES: 0.39 (0.18–0.59) at W26 in favor of
IA HA
baseline ES: 0.46 (0.28–0.65) at W8 Positive
0.21 (0.10–0.31) at W24
baseline 30% Pain over IA placebo effect (10 mm
on VAS)
Intermediate
control at ES: 0.37 (0.46 to 0.28) Positive but
discussed
dpoint SMD: 0.38–0.43 for pain; 0.32–0.34 for
function
Positive
Hedges's g: 0.07 (0.24 to 0.10) No difference
3; SMD ES: IA versus oral placebo 0.29 (0.04–0.54)
4 paracetamol
Positive
HA versus IA placebo 0.34 (0.26–0.42)
ht; SMD, standardized mean difference; VAS, visual analog scale; W, week; WMD;
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week 8 in the Bannuru meta-analysis, and ES of 0.37 (95% CI: 0.46–
0.28) in the Rutjes meta-analysis [2,3]. A further analysis of trials
directly comparing IA HA and NSAIDs suggests that the effect of IA
HA is not signiﬁcantly different from continuous oral NSAIDs in the
short term, at 4 and 12 weeks for pain, function, and stiffness in
knee OA [9]. Injection site pain was the most common adverse
event (AE) reported in the HA group, and gastrointestinal (GI)
AEs were more common in the NSAIDs group. Given the favorable
safety proﬁle of IA HA over NSAIDs, this result suggests that
IA HA might be a good alternative to NSAIDs for knee OA,
especially for older patients or in those at greater risk for NSAID-
induced AEs [1].
IA HA has a long lasting effect on pain in OA [2,10,11]. A recent
analysis of 29 studies (n ¼ 4866) of US-approved IA HA injections
versus placebo found a large treatment effect from 4 weeks up to
26 weeks for knee pain and function compared to pre-injection
values [10]. Compared to saline controls, standardized mean
difference (SMD) with IA HA was maintained at 0.38 for knee pain
and 0.32 for knee function at weeks 14–26 (p o 0.0.001), which
equates to a moderate but true effect [10]. A therapeutic trajectory
of IA HA versus placebo found that IA HA is efﬁcacious by 4 weeks
(ES: 0.31; 95% CI: 0.17–0.45), reaching a peak in effectiveness at
8 weeks (ES: 0.46, 95% CI: 0.28–0.65), and with a residual
detectable effect for knee OA pain at 6 months post-intervention
(ES: 0.21, 95% CI: 0.10–0.31) [2]. In addition, IA HA induces longer-
lasting pain control compared with IA corticosteroids [11]. Analysis
of 7 head-to-head randomized clinical trials (RCTs) of 606 partic-
ipants, found that the pattern of relative efﬁcacy varied over time
following injection. From baseline to week 4, IA corticosteroids
were relatively more effective for pain than IA HA, but by week
4 the two approaches had equal efﬁcacy, and beyond week 8 up to
26 weeks IA HA had greater efﬁcacy (Table 3) [11].Evidence from real-life studies and surveys
HA is not a rapidly acting agent, rather its clinical effect on pain
and function shows a carryover effect that extends for a long time
after administration. The long-term effects of HA on disease
progression over 40 months have been investigated in the Osteo-
Arthritis Modifying Effects of Long-term Intra-articular Adant
(AMELIA) study [19]. The study followed 306 patients with knee
OAwho received 4 cycles of 5 injections of IA HA or placebo, for up
to a year after the fourth cycle. At the end of the study
(40 months), signiﬁcantly more patients receiving HA responded
to treatment compared with placebo according to OARSI 2004
criteria for pain, function, and patient global assessment [80.5% of
responders to HA versus 65.8% for placebo; relative risk (RR): 1.22,
95% CI: 1.07–1.41; p ¼ 0.004] [19]. The number of responders to
HA injections progressively increased after each treatment cycle,
while response to placebo remained fairly stable, with a signiﬁcant
difference between groups evident from 1 year onwards (p oTable 3
Comparative effect of intra-articular hyaluronic acid and corticosteroids on pain in
knee osteoarthritis over time [11]
Weeks from injection Effect size (95% CI) Favors
Week 2 0.39 (0.56 to 0.12) CS 4 HA
Week 4 0.01 (0.23 to 0.21) CS ¼ HA
Week 8 0.22 (0.05 to 0.49) HA ¼ CS
Week 12 0.35 (0.03–0.66) HA 4 CS
Week 26 0.39 (0.18–0.59) HA 4 CS
Analysis of 7 clinical trials (N ¼ 606; HA, n ¼ 312; CS, n ¼ 298); CS, corticosteroid;
HA, hyaluronic acid; IA, intra-articular.0.05). In other observational studies, IA HA injections in knee OA
were highly effective in improving resting and walking pain with
duration of symptom control up to 6 months, and a reduction in
concomitant analgesia use of 30–50%. Few AEs were reported,
mostly limited to mild or moderate local AEs of transient pain and
swelling [20–22].
The impact of HA on further long-term outcomes, namely delay
of total knee replacement (TKR) surgery, has not, as yet, been
studied in prospective, controlled studies; however, it has been
investigated in retrospective works. In a retrospective database
analysis [23], patients enrolled in the database from 2007 to 2011
who went on to TKR were identiﬁed as having received prior
HA injections (n ¼ 7000) or no HA injections (n ¼ 19,627).
A propensity scoring method was implemented to adjust for
baseline characteristics of patients in HA (n ¼ 6891) and non-
HA cohorts. The analysis found that each course of HA injections
delayed patients' progression to TKR, with each treatment course
increasing the median gap by an average 202 days. After 4 or more
treatment courses, a delay in TKR of approximately 2.2 years was
found in the study population [23]. This is in agreement with a
previous 6-year retrospective database study that found a median
delay in TKR of 2.1 years with HA treatment in patients with grade
IV severe OA [24]. The median times from the initial specialist visit
to TKR were 199 and 443 days for non-HA cohort and the HA
cohort with 1 episode of HA treatment, respectively. For the HA
cohort with 3 and 4 or more treatment episodes, the median times
to TKR were 784 (585 days delay) and 1009 days (810 days delay),
respectively (Fig. 1) [23]. In another Spanish study which looked at
the management of knee OA patients referred to orthopedic
surgeons for TKR, the authors reported a mean delay to TKR of
2.2 years among patients who had received treatment with IA HA
injections (using a mathematical modelization) [25].Does molecular weight of HA matter?
HA is a glycosaminoglycan constituent of synovial ﬂuid and
cartilage matrix in normal joints. The properties of the synovial
ﬂuid are dependent on the concentration of HA and its molecular
weight (MW); in OA, the concentration and MW of HA are
decreased [26]. The exogenous HA available for IA viscosupple-
mentation is formulated as different MW preparations: low (range:
500,000–730,000 Da), intermediate (800,000–2,000,000 Da), and
high MW (average: 6,000,000 Da) including cross-linked formula-
tions of HA (hylans).
The precise mechanism of action of exogenous HA is unknown.
However, the proposed mechanism of HA activity occurs in
2 stages: a mechanical stage and a pharmacological stage [11,27].
During the mechanical stage, OA synovial ﬂuid is replaced by
higher concentrations of HA thereby improving viscosity [28]. This
also restores the shock-absorbing and lubricating abilities of
depleted synovial ﬂuid and maintains a boundary layer around
nociceptors, reducing pain induction [29]. The pharmacological
stage induces the biosynthesis of endogenous HA and extracellular
matrix components [30], which reduces proteoglycan loss in
cartilage and apoptosis of chondrocytes [28,31]. It also reduces
inﬂammatory cell activities to reduce HA degradation and acts by
reducing induction of pain mediators [28,29].
The endogenous synthesis of HA by synovial ﬁbroblasts is
inﬂuenced by the concentration and MW of HA in the extracellular
environment (Fig. 2) [30]. With low MW HA preparations only
weak binding occurs and the biosynthesis of HA may not be
sufﬁciently stimulated. With exogenous HA of intermediate MW,
strong binding occurs and because of the high number of receptors
stimulated endogenous HA biosynthesis is enhanced. While max-
imal receptor binding occurs with high MW HA, the large domains
Fig. 1. Impact of repeat episodes of intra-articular hyaluronic acid injections on time to total knee replacement (TKR) surgery [23]. (Reproduced with permission from Abbott
et al. [23]; copyright permission granted.)
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on the cell surface, and HA biosynthesis may not be strongly
stimulated by such a conﬁguration [30]. There is also some
evidence that low MW HA could have proinﬂammatory activity
on chondrocytes, while intermediate MW preparations would be
neutral in in vitromodels [32]. However, whether these in vitro data
translate into clinical evidence is as yet uncertain. It has been
suggested by Aviad and Houp [33] that the concentration of HA
injections may be more important than the MW of HA regarding
the clinical effect.
Most head-to-head clinical trials performed to date have found
non-inferiority with respect to symptomatic efﬁcacy between the
HA preparations of various MWs tested [34–38]. In a head-to-head
clinical trial of 3-weekly injections of intermediate MW HA
(GO-ONs) versus low MW HA (Hyalgan) in over 400 knee OA
patients, the intermediate MW HA preparation was statistically
superior for the primary endpoint of Western Ontario and
McMaster Universities (WOMAC) pain subscale score at 6 months
after the end of treatment; mean WOMAC pain score decreased by
22.9 7 1.4 mm with intermediate MW HA and 18.4 7 1.5 mm
with low MW HA after 6 months (p ¼ 0.021) (Fig. 3) [26]. AtFig. 2. Model of hyaluronic acid binding to receptors on the surface of synovial ﬁbroblast
[30].)6 months although both groups exhibited a high proportion of
responders, there were signiﬁcantly more OARSI/OMERACT res-
ponders in the intermediate MWHA group compared with the low
MW HA group (73% versus 58%; p ¼ 0.001) [26]. A meta-analysis
found no clinically relevant difference in beneﬁt of hylan com-
pared with lower MW HA preparations (1 low MW and 1 inter-
mediate MW) but with an increased safety risk for hylan [17].
Therefore, overall, the current evidence available does not support
a superiority of one kind of MW HA preparation over another,
perhaps with the exception of a slightly lower efﬁcacy for low MW
preparations versus intermediate and high MW HA shown in
a single trial which requires further investigation.Which patients are likely to respond best to IA HA?
This is a major issue. Unfortunately, little evidence can be found
in the available literature, either from clinical trials, or surveys of
long-term HA use [39]. Summarizing this limited evidence leads to
the following suggestions; IA HA injections seem to be more
effective if the patient:s [30]. HA, hyaluronic acid; MW, molecular weight. (Adapted from Smith and Ghosh
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Fig. 3. WOMAC pain subscale score change for intermediate MW HA (GO-ONs)
(n ¼ 217) versus low MW HA (Hyalgans) (n ¼ 209), ITT mean (and SE) change
from baseline [WOMAC pain subscale index score (0–100 scale): 47.5 7 14.3 for the
GO-ON group and 48.8 7 14.9 for the Hyalgan group] [26]. The arrows indicate the
intra-articular injections. (Reproduced with permission from Berenbaum et al. [26];
copyright permission granted.)
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rence grade 2, rather than 3) [39],2. is not too old [34], and
3. has a high level of symptoms. Karlsson et al. [34] showed that
patients with a Lequesne index of at least 10 had a better
response.
In addition, the presence of crystals in the joint does not
preclude the use of HA injections, and does not reduce the level
of response [40,41]. Furthermore, a certain level of physical activity
seems to be associated with better results (unpublished data from
the Berenbaum trial) [26].Safety of IA HA
IA HA injections are widely reported to be relatively safe, and a
meta-analysis of US-approved HA products on knee OA found no
statistically signiﬁcant difference between IA HA and saline con-
trols for any safety outcome [10]. Furthermore, the serious AE risk
was similar between IA HA and saline (risk difference: 0.7%; 95%
CI: 0.2% to 1.5%; p ¼ 0.12) [10]. The safety record of IA HA has
recently been questioned by a meta-analysis that reported an
increased risk of side effects (serious AEs and local AEs) with HA
that barely reached signiﬁcance, and was limited to a small select
fraction of trials (8 out of 71) [3]. It is important to note that the
considered studies were of poor methodological and reporting
quality, rendering the ﬁndings questionable [42]. Pseudoseptic
reactions have been reported in a small number of cases, occurring
more often with cross-linked formulations of the highest MW [43].
A meta-analysis on safety found that high MW, cross-linked
formulations of HA (hylans) are twice as likely to cause local
adverse reactions (RR: 1.91; 95% CI: 1.04–3.49; I2 ¼ 28%) and post-
injection ﬂares (RR: 2.04; 95% CI: 1.18–3.53; I2 ¼ 0%) compared
with intermediate or low MW HA [17].Conclusions
There is good evidence for the efﬁcacy of IA HA in reducing pain
and increasing function in knee OA as demonstrated in RCTs.
While IA corticosteroids show early relief of symptoms, IA HA
demonstrates a greater effect beyond 12 weeks after injection, and
with longer lasting beneﬁts up to 6 months. Evidence from a real-
life study of repeat courses of IA HA demonstrates an improve-
ment in pain or function lasting up to 40 months (12 months afterthe last treatment cycle). Other observational studies suggest a
reduction in use of concomitant analgesia by up to 50%, and a
delay in the need for TKR surgery of around 2 years. This particular
outcome should be further studied in prospective long-term
controlled trials or surveys.
The clinical beneﬁts of IA HA on knee OA may be considered to
be 2-fold: (i) mechanical viscosupplementation of the joint allow-
ing lubrication and shock absorption and (ii) the re-establishment
of joint homeostasis through induction of endogenous HA pro-
duction, which continues long after the exogenous injection has
left the joint. The magnitude of the clinical effect for different HA
products may vary, and this also requires further prospective
controlled investigations to be established. IA HA injections are
generally considered to be safe, with only mild to moderate
transient local AEs reported on the whole, although a slightly
higher occurrence of local reactions and ﬂares has been reported
with hylans.
Further investigation into the OA patient phenotypes most
likely to beneﬁt from IA HA is warranted. However, the ESCEO
recommends the use of IA HA in knee OA patients with mild to
moderate disease, and for more severe patients who are either
contraindicated to TKR surgery or wishing to delay the surgical
procedure. Viscosupplementation with IA HA appears to be a safe
and effective treatment and should be kept as a component of the
multi-modal management of knee OA.Acknowledgments
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